Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2014 Mar;3(2):115-22.
doi: 10.2217/cns.14.2.

Nanocarrier-based therapies for CNS tumors

Toral R Patel  1
Affiliations
Review

Nanocarrier-based therapies for CNS tumors

Toral R Patel. CNS Oncol. 2014 Mar.

Abstract

Current chemotherapeutic strategies for tumors of the CNS are largely ineffective. This is due, in part, to the lack of robust drug delivery systems. The blood-brain barrier hinders the passage of systemically delivered therapeutics, and the brain extracellular matrix limits the distribution and longevity of locally delivered agents. Drug-loaded nanocarriers represent a promising strategy to overcome these barriers. Due to their small size and versatile design, nanocarriers can be finely tuned to address specific drug delivery challenges. Here, we review the major advances in development of nanocarrier-based therapeutics for tumors of the CNS, with an emphasis on polymeric nanoparticles.

Keywords: blood–brain barrier; brain; convection-enhanced delivery; dendrimer; intracranial; liposome; micelle; nanocarrier; nanoparticle; polymer; systemic delivery.

PubMed Disclaimer

Conflict of interest statement

Financial disclosure

The author is part of a pending patent application on a drug-loaded nanocarrier for glioblastoma. The author has no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

No writing assistance was utilized in the production of this manuscript.

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Stupp R, Mason WP, van den Bent MJ. Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma. N. Engl. J. Med. 2005;352(10):987–996. - PubMed

    2. •• Describes the current standard-of-care for malignant gliomas.

    1. Hochberg FH, Pruitt A. Assumptions in the radiotherapy of glioblastoma. Neurology. 1980;30(9):907–911. - PubMed
    1. Yang H. Nanoparticle-mediated brain-specific drug delivery, imaging, and diagnosis. Pharm. Res. 2010;27(9):1759–1771. - PMC - PubMed
    1. Zagouri F, Sergentanis TN, Bartsch R. Intrathecal administration of trastuzumab for the treatment of meningeal carcinomatosis in HER2-positive metastatic breast cancer: a systematic review and pooled analysis. Breast Cancer Res. Treat. 2013;139(1):13–22. - PubMed
    1. Abbott NJ, Ronnback L, Hansson E. Astrocyte–endothelial interactions at the blood–brain barrier. Nat. Rev. Neurosci. 2006;7(1):41–53. - PubMed

MeSH terms

LinkOut - more resources